Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 7/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10134770 | 0.87 | CSNK2A1 (0.45) | CSNK2A1ABCG2CSNK2A2CSNK2BEGFR | |
| SCHEMBL13688039 | 0.84 | EGFR (0.61) | CSNK2A1ABCG2CSNK2A2CSNK2BEGFR | |
| SCHEMBL10134755 | 0.84 | CSNK2A1 (0.45) | CSNK2A1ABCG2CSNK2A2CSNK2B | |
| SCHEMBL10134753 | 0.81 | ABCG2 (0.43) | CSNK2A1ABCG2CSNK2A2CSNK2BTSHR | |
| SCHEMBL10134812 | 0.80 | CSNK2A1 (0.72) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL10134830 | 0.78 | CSNK2A1 (0.58) | CSNK2A1ABCG2CSNK2A2CSNK2BTSHR | |
| SCHEMBL10134757 | 0.78 | CSNK2A1 (0.42) | CSNK2A1ABCG2CSNK2A2CSNK2BEGFR | |
| SCHEMBL10134763 | 0.77 | CSNK2A1 (0.46) | TDO2CSNK2A1ABCG2CSNK2A2CSNK2B | |
| SCHEMBL10134787 | 0.76 | CSNK2A1 (0.49) | CSNK2A1ABCG2CSNK2A2CSNK2BEGFR | |
| SCHEMBL10135169 | 0.71 | CSNK2A1 (0.59) | CSNK2A1ABCG2CSNK2A2CSNK2BEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | TDO2 3257/4885CSNK2A1 680/4885ABCG2 2980/4885 |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | TDO2 3257/4885CSNK2A1 680/4885ABCG2 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.